Montgomery County, Pennsylvania — February 18, 2026 — Leads & Copy — Johnson & Johnson (NYSE: JNJ) is investing over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
The new facility will expand Johnson & Johnson’s U.S. manufacturing capacity and advance its portfolio of medicines for cancer, immune-mediated, and neurological diseases. The investment aims to unite scientific excellence with state-of-the-art manufacturing.
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, stated the company is honored to continue its legacy in Pennsylvania. He added the company is delivering for patients and creating opportunities for workers and families through strategic investment and community collaboration.
The facility will support over 500 skilled biomanufacturing jobs and more than 4,000 construction jobs during site development. Johnson & Johnson is investing in manufacturing processes and training to develop a skilled workforce in advanced technologies.
Pennsylvania Governor Josh Shapiro said that Pennsylvania is a powerhouse for innovation and manufacturing in the life sciences. He said the state has been cutting red tape and making strategic investments in key industries like the life sciences to ensure success.
The investment strengthens Johnson & Johnson’s economic impact across Pennsylvania, which totals approximately $10 billion annually. The company has ten facilities in Pennsylvania, encompassing over 2 million square feet for manufacturing, research, distribution, and office operations.
The announcement is part of the Company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.
U.S. Senator Dave McCormick noted Pennsylvania’s skilled workforce, research institutions, and manufacturing strength allow companies like Johnson & Johnson to succeed. He said that the investment will produce life-changing treatments and new jobs for the Commonwealth.
U.S. Senator John Fetterman stated he is proud to see the investment into Montgomery County and the Commonwealth.
Representative Madeleine Dean said the opening of Johnson & Johnson’s cell therapy manufacturing facility expands its tradition of leadership in Pennsylvania. She added that the new site will promote job growth, foster innovation, and bring medicine to people around the country.
Learn more at https://www.jnj.com/ or at https://innovativemedicine.jnj.com/. Follow us at @JNJInnovMed.
Source: Johnson & Johnson
